Daiichi Sankyo has appointed Ken Keller to the newly created role of Chief Commercialization Officer, responsible for accelerating further growth of the company’s oncology and specialty medicine business through a new globally integrated Commercialization Unit, effective April 1, 2027.
As part of the operational excellence pillar outlined in the new Five-Year Business Plan of Daiichi Sankyo in May 2026, commercialization activities will be centralized and reorganized to drive greater speed and consistency, while optimizing resource management and investment decisions as part of the company’s ambition to become a global top five oncology company by 2035.
“Over the past decade, Ken has played a pivotal role in advancing the commercial capabilities of Daiichi Sankyo and has been instrumental in the successful launches of Enhertu and Datroway , our two lead DXd antibody drug conjugates. Enhertu has become the most successful antibody drug conjugate by both number of approved indications and revenue, reflecting the strength of the commercial foundation Ken has helped build,” said Hiroyuk Okuzawa, President and CEO of Daiichi Sankyo. “Ken’s leadership also has been central to bringing important rare disease and supportive care medicines to patients such as Vanflyta , Turalio and Injectafer , demonstrating the breadth and depth of his experience. His proven track record, strategic insight and leadership make him the right person to serve as our new Chief Commercialization Officer.”
“Taking on this role at Daiichi Sankyo during this pivotal period of accelerated growth is an honor,” said Ken Keller.
“As we look to the future, I am excited to help lead the continued transformation of Daiichi Sankyo into a global top
five oncology company defined by innovation, scientific excellence and long-term impact for patients. We have an
extraordinary opportunity to build on our strong foundation, advance groundbreaking medicines and create lasting
value for patients, healthcare providers and the communities we serve globally.”